secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2026-07-15T21:14:18+00:00
Accession:  0001193125-26-304949
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Decoy Therapeutics Stockholders Re-elect Directors, Approve Executive Pay and Auditor at 2026 Annual Meeting
--------------------------------------------------------------------------------

- Quorum of 42.4% (225,548 of 531,968 shares) present at July 14, 2026 Annual Meeting.
- Class II directors Patricia Gauthier, Jonathan Lieber, and Frederick E. Pierce re-elected with 23,204, 22,964, and 22,690 votes for, respectively.
- Non-binding advisory vote on named executive officer compensation passed with 21,278 votes for, 5,041 against, and 1,007 abstentions.
- Ratification of Ernst & Young LLP as independent auditor for FY2026 approved with 214,341 votes for, 9,584 against, 1,623 abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000119312526304949/0001193125-26-304949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000119312526304949/dcoy-20260714.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-304949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer